Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

Journal of Virology

Volumn 77, Issue 5, 2003, Pages 3119-3130

  Dong, Ming ^a   Zhang, Peng Fei ^a   Grieder, Franziska ^a,e   Lee, James ^a   Krishnamurthy, Govindaraj ^a   VanCott, Thomas ^b   Broder, Christopher ^a   Polonis, Victoria R ^b   Yu, Xiao Fang ^c   Shao, Yiming ^d   Faix, Dennis ^a   Valente, Patricia ^a,f   Quinnan Jr , Gerald V ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b H M Jackson Found Adv Mil Med   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d National AIDS Reference Laboratory   (China)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f National Institutes of Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ALPHA VIRUS; ANIMAL EXPERIMENT; ARTICLE; CLADISTICS; CROSS REACTION; FRACTIONATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN SECRETION; RABBIT; REPLICON; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; CROSS REACTIONS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; REPLICON;

EID: 0037370634     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.5.3119-3130.2003     Document Type: Article

References (36)

1. Beirnaert, E., P. Nyambi, B. Willems, L. Heyndrickx, R. Colebunders, W. Janssens, and G. van Der. 2000. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J, Med. Virol. 62:14-24.
2. Browning, J., J. W. Horner, M. Pettoello-Mantovani, C. Raker, S. Yurasov, R. A. DePinho, and H. Goldstein. 1997. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc. Natl. Acad. Sci. USA 94: 14637-14641.
3. Caley, I. J., M. R. Betts, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1999. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17:3124-3135.
4. Caley, I. J., M. R. Betts, D. M. Irlbeck, N. L. Davis, R. Swanstrom, J. A. Frelinger, and R. E. Johnston. 1997, Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type I immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:3031-3038.
5. Charles, P. C., K. W. Brown, N. L. Davis, M. K. Hart, and R. E. Johnston. 1997. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 228:153-160.
6. Connor, R. I., B. T. Korber, B. S. Graham, B. H. Hahn, D.-D. Ho, B. D. Walker, A. U. Neumann, S. H. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. J. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. P. Moore, and S. M. Wolinsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
7. Davis, N. L., K. W. Brown, and R. E. Johnston. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787.
8. Davis, N. L., I. J. Caley, K. W. Brown, M. R. Betts, D. M. Irlbeck, K. M. McGrath, M. J. Connell, D. C. Montefiori, J. A. Frelinger, R. Swanstrom, P. R. Johnson, and R. E. Johnston. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74:371-378.
9. Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith, and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183:20-31.
10. Davis, N. L., L. V. Willis, J. F. Smith, and R. E. Johnston. 1989. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171:189-204.
11. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
12. D'Souza, M. P., P. Durda, C. V. Hanson, G. Milman, et al. 1991. Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. AIDS 5:1061-1070.
13. Earl, P. L., C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. 1994. Native oligomeric human immunodeficiency virus type I envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
14. Earl, P. L., W. Sugiura, D. C. Montefiori, C. C. Broder, S. A. Lee, C. Wild, J. Lifson, and B. Moss. 2001. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 75:645-653.
15. Grieder, F. B., B. K. Davis, X. D. Zhou, S. J. Chen, F. D. Finkelman, and W. C. Gause. 1997. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus. Virology 233:302-312.
16. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006.
17. Hevey, M., D. Negley, P. Pushko, J. Smith, and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251:28-37.
18. Kim, J. H., J. R. Mascola, S. Ratto-Kim, T. C. Vancott, L. Loomis-Price, J. H. Cox, N. L. Michael, L. Jagodzinski, C. Hawkes, D. Mayers, B. L. Gilliam, D. C. Birx, and M. L. Robb. 2001. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res. Hum. Retrovir. 17:1021-1034.
19. Levy, J. A. 1993. Pathogenesis of human immunodeficiency virus infection. Microbial. Rev. 57:183-289.
20. Moore, J. P., and D. C. Montefiori. 1997. Neutralization assays using the BZ167 strain of human immunodeficiency virus type 1. J. Infect. Dis, 176: 1410-1412.
21. Park, E. J., and G. V. Quinnan. 1999. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the HIV-1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J. Virol. 73:5707-5713.
22. Park, E. J., L. K. Vujcic, R. Anand, T. S. Theodore, and G. V. Quinnan, Jr. 1998. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 72:7099-7107.
23. Park, E. J., S. Zolla-Pazner, and G. V. Quinnan, Jr. 2000. Distinct mechanisms mediating enhanced infectivity and envelope conformational change determine global neutralization resistance phenotype of HIV-1. J. Virol. 74:4183-4191.
24. Pushko, P., M. Bray, G. V. Ludwig, M. Parker, A. Schmaljohn, A. Sanchez, P. B. Jahrling, and J. F. Smith. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153.
25. Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997, Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401.
26. Quinnan, G. V., P. F. Zhang, D. W. Fu, M. Dong, H. J. Alter, et al. 1999. Expression and characterization of HIV type I envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res. Hum. Retrovir. 15:561-570.
27. Quitman, G. V., P. F. Zhang, D. W. Fu, M. Dong, and J. B. Margolick. 1998. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res. Hum. Retrovir. 14:939-949.
28. Richardson, T. M. J., B. L. Stryjewski, C. C. Broder, J. A. Hoxie, J. R. Mascola, P. L. Earl, and R. W. Doms. 1996. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol. 70:753-762.
29. Schoneboom, B. A., J. S. Lee, and F. B. Grieder. 2000. Early expression of IFN-α/β and iNOS in the brains of Venezuelan equine encephalitis virus-infected mice. J. Interferon Cytokine Res. 20:205-215.
30. Steinhoff, U., U. Muller, A. Schertler, H. Hengartner, M. Aguet, and R. M. Zinkernagel. 1995. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J. Virol. 69: 2153-2158.
31. Stuve, L. L., S. Brown-Shimer, C. Pachl, R. Najarian, D. Dina, and R. L. Burke. 1987. Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J. Virol. 61:326-335.
32. Sugiura, W., C. C. Broder, B. Moss, and P. L. Earl. 1999. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type I envelope proteins. Virology 254:257-267.
33. Vujcic, L., D. Katzenstein, M. Martin, and G. Quinnan. 1990. International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. AIDS Res. Hum. Retrovir. 6:847-853.
34. Vujcic, L. K., and G. Quinnan. 1995. Preparation and characterization of human HIV type I neutralizing reference sera. AIDS Res. Hum. Retrovir. 1:783-787.
35. Zhang, P. F., P. Bouma, E. J. Park, J. B. Margolick, J. E. Robinson, S. Zolla-Pazner, M. N. Flora, and G. V. Quinnan, Jr. 2002. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response, J. Virol. 76:644-655.
36. Zhang, P. F., X. Chen, D. W. Fu, J. B. Margolick, and G. V. Quinnan, Jr. 1999. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. J. Virol. 73:5225-5230.